Biomarkers for seizures

Abstract

The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject. Also provided are methods for detecting seizure, methods for predicting seizure, use of sICAM-5 in the treatment of seizure, methods for assessing the effectiveness of a treatment of seizure, and diagnostic kits.

1 . A polypeptide expression panel or array, said panel or array comprising:
 a probe capable of binding soluble ICAM-5 (sICAM-5) in blood plasma or blood serum of a mammalian subject; and   a probe capable of binding TARC in blood plasma or blood serum of said mammalian subject;   wherein a decreased plasma or serum concentration of sICAM-5 in said mammalian subject in combination with an increased plasma or serum concentration of TARC in said mammalian subject indicates a tendency to have seizure.   
     
     
         2 . The polypeptide expression panel or array according to  claim 1 , wherein said decreased plasma or serum concentration of sICAM-5 and said increased plasma or serum concentration of TARC are relative to concentrations in a healthy control. 
     
     
         3 . The polypeptide expression panel or array according to  claim 1 , wherein said decreased plasma or serum concentration of sICAM-5 and said increased plasma or serum concentration of TARC are relative to prior concentrations in said blood plasma or blood serum of said mammalian subject. 
     
     
         4 . (canceled) 
     
     
         5 . The polypeptide expression panel or array according to  claim 1 , further comprising a probe capable of binding IL-8, wherein an increased plasma or serum concentration of IL-8 indicates a tendency to have seizure. 
     
     
         6 . The polypeptide expression panel or array according to  claim 1 , further comprising a probe capable of binding IL-2, wherein an increased plasma or serum concentration of IL-2 indicates a tendency to have seizure. 
     
     
         7 . The polypeptide expression panel or array according to  claim 1 , further comprising a probe capable of binding IL-1β, wherein an increased plasma or serum concentration of IL-1β indicates a tendency to have seizure. 
     
     
         8 . The polypeptide expression panel or array according to  claim 1 , further comprising a probe capable of binding IFN-γ, wherein an increased plasma or serum concentration of IFN-γ indicates a tendency to have seizure. 
     
     
         9 . The polypeptide expression panel or array according to  claim 1 , further comprising probes capable of binding one or more of IL-10, IL-12 p70, Fas, Fas-ligand, MCP-1, MDC, MIP-1β, GM-CSF, MCP-4, IP-10, BDNF, Eotaxin-3, Eotaxin, and TNF-α, wherein an altered plasma or serum concentration of one or more of IL-10, IL-12 p70, Fas, Fas-ligand, MCP-1, MDC, MIP-1β, GM-CSF, MCP-4, IP-10, BDNF, Eotaxin-3, Eotaxin, and TNF-α indicates a tendency to have seizure. 
     
     
         10 - 13 . (canceled) 
     
     
         14 . A method for predicting or detecting seizure in a mammalian subject comprising:
 contacting a blood plasma or blood serum sample obtained from a mammalian subject with a diagnostic reagent that can measure or detect the expression level of soluble ICAM-5 (sICAM-5); and   contacting said blood plasma or blood serum sample obtained from a mammalian subject with a diagnostic reagent that can measure or detect the expression level of TARC;   wherein a decreased plasma or serum concentration of sICAM-5 in said blood plasma or blood serum sample of said mammalian subject, in combination with an increased plasma or serum concentration of TARC in said blood plasma or blood serum sample of said mammalian subject, indicates a tendency to have seizure.   
     
     
         15 . The method of  claim 14 , wherein said decreased plasma or serum concentration of sICAM-5 and said increased plasma or serum concentration of TARC are relative to concentrations in a healthy control. 
     
     
         16 . The method of  claim 14 , wherein said decreased plasma or serum concentration of sICAM-5 and said increased plasma or serum concentration of TARC are relative to prior concentrations in said blood plasma or blood serum sample of said mammalian subject. 
     
     
         17 . (canceled) 
     
     
         18 . The method of  claim 14 , further comprising contacting said blood plasma or blood serum sample obtained from a mammalian subject with a diagnostic reagent that can measure or detect the expression level of IL-8, wherein an increased plasma or serum concentration of IL-8 indicates a tendency to have seizure. 
     
     
         19 . The method according to  claim 14 , further comprising contacting said blood plasma or blood serum sample obtained from a mammalian subject with a diagnostic reagent that can measure or detect the expression level of IL-2, wherein an increased plasma or serum concentration of IL-2 indicates a tendency to have seizure. 
     
     
         20 . The method according to  claim 14 , further comprising contacting said blood plasma or blood serum sample obtained from a mammalian subject with a diagnostic reagent that can measure or detect the expression level of IL-1β, wherein an increased plasma or serum concentration of IL-1β indicates a tendency to have seizure. 
     
     
         21 . The method according to  claim 14 , further comprising contacting said blood plasma or blood serum sample obtained from a mammalian subject with a diagnostic reagent that can measure or detect the expression level of IFN-γ, wherein an increased plasma or serum concentration of IFN-γ indicates a tendency to have seizure. 
     
     
         22 . The method according to  claim 14 , further comprising contacting said blood plasma or blood serum sample obtained from a mammalian subject with one or more diagnostic reagents that can measure or detect the expression level of one or more of IL-10, IL-12 p70, Fas, Fas-ligand, MCP-1, MDC, MIP-1β, GM-CSF, MCP-4, IP-10, BDNF, Eotaxin-3, Eotaxin, and TNF-α, wherein an altered plasma or serum concentration of one or more of IL-10, IL-12 p70, Fas, Fas-ligand, MCP-1, MDC, MIP-1β, GM-CSF, MCP-4, IP-10, BDNF, Eotaxin-3, Eotaxin, and TNF-α indicates a tendency to have seizure. 
     
     
         23 - 41 . (canceled) 
     
     
         42 . A method of treating or preventing seizure or a disorder for which seizure is symptomatic in a mammalian subject, comprising delivering a therapeutically effective amount of sICAM-5. 
     
     
         43 . The method according to  claim 42 , wherein said sICAM-5 is delivered intravenously. 
     
     
         44 . The method according to  claim 42 , wherein said sICAM-5 is delivered intra-cerebral spinal fluid (intra-CSF). 
     
     
         45 . The method according to  claim 42 , wherein said sICAM-5 is delivered intranasally to the cerebral spinal fluid (CSF). 
     
     
         46 . (canceled)